Schedules of Controlled Substances: Placement of 3-Methoxyphencyclidine (1-(1-(3-Methoxyphenyl)cyclohexyl)piperidine) in Schedule I
Comments Off on Schedules of Controlled Substances: Placement of 3-Methoxyphencyclidine (1-(1-(3-Methoxyphenyl)cyclohexyl)piperidine) in Schedule I
May 8, 2026
✦ New CED Clinical Relevance #70 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Policy Watch | Federal Register PolicySafetyResearch Clinical Summary This regulatory action places…
Schedules of Controlled Substances: Placement of Butonitazene, Flunitazene, and Metodesnitazene in Schedule I
Comments Off on Schedules of Controlled Substances: Placement of Butonitazene, Flunitazene, and Metodesnitazene in Schedule I
March 8, 2026
✦ New CED Clinical Relevance #70 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Policy Watch | Regulations.gov PolicySafetyResearch Why This Matters I don’t see a summary…